Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Department of Intensive Care Unit of Cardiac Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
Microbiol Spectr. 2022 Jun 29;10(3):e0012522. doi: 10.1128/spectrum.00125-22. Epub 2022 Jun 6.
The effects of using gut microbiota metabolites instead of live microorganisms to modulate sepsis-induced gut dysbiosis remain largely unknown. We assessed the effects of microbiota metabolite indole-3-propionic acid (IPA) on gut microbiota in mice during sepsis. Sepsis models were constructed by cecal ligation and puncture (CLP) methods. Fecal microbiota composition analysis was performed to characterize the gut microbiota composition. Fecal microbiota transplantation was performed to validate the roles of gut microbiota on sepsis progression. IPA-treated mice exhibited lower serum inflammatory mediator levels and a higher survival rate than those of saline-treated mice after modeling of sepsis, which were negated in the presence of antibiotics. Compared with saline-treated mice after modeling, IPA-treated mice showed a markedly different intestinal microbiota composition, with an enrichment of family and a depletion of family. Mice gavaged with postoperative feces from IPA-treated animals displayed better survival than mice gavaged with feces from saline-treated animals. Overall, these data suggest that IPA offers a microbe-modulated survival advantage in septic mice, indicating that some microbiota metabolites could replace live microorganisms as potential options for regulation of sepsis-induced gut dysbiosis. The role of gut microbiota in the pathophysiology of sepsis is gaining increasing attention and developing effective and safe sepsis therapies targeting intestinal microorganisms is promising. Given the safety of probiotic supplementation or fecal microbiota transplantation in critically ill patients, identifying an abiotic agent to regulate the intestinal microbiota of septic patients is of clinical significance. This study revealed that IPA, a microbiota-generated tryptophan metabolite, ameliorated sepsis-induced mortality and decreased the serum levels of proinflammatory cytokines by modulating intestinal microbiota. Although IPA did not increase the abundance and diversity of the microbiota of septic mice, it significantly decreased the number of family. These findings indicate that a specific microbiota metabolite (e.g., IPA) can mediate the intestinal microbiota apart from FMT or probiotics.
使用肠道微生物代谢物而非活体微生物来调节脓毒症引起的肠道菌群失调的效果在很大程度上尚不清楚。我们评估了微生物代谢物吲哚-3-丙酸(IPA)在脓毒症期间对小鼠肠道微生物群的影响。通过盲肠结扎和穿刺(CLP)方法构建脓毒症模型。进行粪便微生物群落分析以表征肠道微生物群落组成。进行粪便微生物群移植以验证肠道微生物群对脓毒症进展的作用。与脓毒症模型建立后的盐水处理组小鼠相比,IPA 处理组小鼠的血清炎症介质水平较低,存活率较高,而在使用抗生素的情况下则相反。与建模后接受盐水处理的小鼠相比,IPA 处理组小鼠的肠道微生物群落组成明显不同,丰度增加,减少。给予 IPA 处理动物术后粪便的小鼠的存活率明显高于给予盐水处理动物术后粪便的小鼠。总的来说,这些数据表明 IPA 为脓毒症小鼠提供了微生物调节的生存优势,表明一些微生物代谢物可以替代活体微生物作为调节脓毒症引起的肠道菌群失调的潜在选择。肠道微生物群在脓毒症发病机制中的作用越来越受到关注,针对肠道微生物的有效和安全的脓毒症治疗方法具有广阔的前景。鉴于在危重病患者中补充益生菌或粪便微生物群移植的安全性,确定一种非生物制剂来调节脓毒症患者的肠道微生物群具有临床意义。本研究表明,肠道微生物群产生的色氨酸代谢物 IPA 通过调节肠道微生物群改善了脓毒症引起的死亡率并降低了促炎细胞因子的血清水平。尽管 IPA 没有增加脓毒症小鼠的微生物群的丰度和多样性,但它显著减少了家族的数量。这些发现表明,一种特定的微生物群代谢物(例如 IPA)可以介导肠道微生物群,而无需 FMT 或益生菌。